Peptide Markers for Systemic Sclerosis Diagnosis and Subgroup Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for systemic sclerosis (SSc) face challenges in accurately diagnosing early stages and distinguishing between SSc subgroups due to the lack of specific biomarkers, with existing autoantibodies showing limited specificity and the need for improved prognostic and predictive markers.
Innovation Solution
Development of peptide markers, specifically short sequences of 35 amino acids or less, which can serve as binding regions or epitopes, to detect systemic sclerosis and differentiate between SSc subgroups, allowing for improved diagnosis, prognosis, and therapy monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing autoantibodies (anti-topoisomerase, anti-centromere, anti-RNAP III) are used for diagnosis, then specificity for SSc is improved, but the ability to differentiate between SSc subgroups and detect early stages is worsened due to limited sensitivity and lack of early detection capability
Solution Approach 1:
The patent segments the diagnostic approach by dividing the autoantibody detection into multiple specific targets: anti-topoisomerase I for diffuse SSc, anti-centromere for limited SSc, and anti-RNAP III for diffuse SSc with renal crisis risk. This segmentation allows each marker to be optimized for specific subgroups, resolving the contradiction between overall specificity and subgroup differentiation accuracy.
Solution Approach 2:
The patent changes the diagnostic parameters by introducing a multi-marker panel system that measures multiple autoantibodies simultaneously with defined cutoff values and interpretation algorithms. This parameter change enables both high specificity (through multiple markers) and accurate subgroup differentiation (through pattern recognition), resolving the contradiction between these two requirements.
2Reliability
If ANA testing is used for early detection, then sensitivity is improved, but specificity is worsened due to positive results in healthy individuals and other collagenoses
Solution Approach 1:
The patent extracts the specific diagnostic value from the general ANA test by focusing on three particular autoantibodies (anti-topoisomerase I, anti-centromere, anti-RNAP III) that are extracted and measured individually. This extraction approach maintains the high sensitivity of ANA screening while achieving high specificity by identifying which specific autoantibodies are present, thereby resolving the contradiction between sensitivity and specificity.
3Ease of operation
If clinical picture and skin changes are used for diagnosis, then diagnostic simplicity is improved, but early stage detection is worsened due to difficulty in classifying undifferentiated SSc
Solution Approach 1:
The patent introduces autoantibody markers as intermediary diagnostic tools that bridge the gap between simple clinical observation and accurate early diagnosis. These markers serve as mediators that provide objective, measurable evidence of SSc presence and subtype, enabling early detection before skin changes become apparent and facilitating accurate classification of undifferentiated cases while maintaining diagnostic simplicity through blood testing.
Data Source
AI summary
The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.